Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that its wholly-owned U.S. subsidiary, Pivot Naturals LLC, (“PNL”), has entered a lease agreement for a manufacturing facility in Costa Mesa, California’s Measure “X” Zone. PNL will immediately submit applications to acquire a Marijuana Business Permit, Conditional Use Permit and Business License. Businesses that meet the requirements to operate in Costa Mesa’s Measure “X” Zone can establish research and development and testing laboratories and are permitted to conduct wholesale medical marijuana distributing, manufacturing, processing and transporting. The company intends to use the building as a state-of-the-art GMP manufacturing facility to begin producing its patented products to be marketed under the brand name ‘Pivot Naturals’. PNL will employ the company’s patented Ready To Infuse Cannabis (“RTIC”) method to convert high quality cannabis oil and isolates to powder for finished products such as capsules, stick packs and bulk additives for sale and distribution in the California market. Additionally, a section of the facility has been set aside to form production lines of topical creams and oral solutions utilizing the company’s other patented drug delivery technologies. “Securing a manufacturing facility in California is a major milestone for Pivot, enabling the company to generate revenue in 2018, in the largest cannabis market in the world,” Dr. Patrick Frankham, Pivot Pharmaeuticals CEO stated in the news release.
To view the full press release, visit http://ibn.fm/cvTyR
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly owned medical cannabis products division, Pivot Green StreamHealth Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol, and tetrahydrocannabinol-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information, visit the company’s website at www.PivotPharma.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
